UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
X Quarterly report pursuant to Section 13 or 15(d) of the Securities
- ----- Exchange Act of 1934. For the quarterly period ended June 30, 2000.
_____ Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934. For the transition period from _____ to _____.
Commission File Number
0-27410
INCARA PHARMACEUTICALS CORPORATION
----------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 56-1924222
------------------------ ------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
P.O. Box 14287
3200 East Highway 54
Cape Fear Building, Suite 300
Research Triangle Park, NC 27709
- ------------------------------------------ ------------
(Address of Principal Executive Office) (Zip Code)
Registrant's Telephone Number, Including Area Code 919-558-8688
------------
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. YES X NO ______
-----
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Class Outstanding as of July 24, 2000
------------- -------------------------------
Common Stock, par value $.001 7,284,261 Shares
INCARA PHARMACEUTICALS CORPORATION
INDEX TO FORM 10-Q
PAGE
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Balance Sheets as of June 30, 2000 (unaudited)
and September 30, 1999............................................ 3
Consolidated Statements of Operations for the Three Months and
Nine Months ended June 30, 2000 and 1999 (unaudited).............. 4
Consolidated Statements of Cash Flows for the Nine Months ended
June 30, 2000 and 1999 (unaudited)................................ 5
Notes to Consolidated Financial Statements........................ 6
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations...................... 9
PART II. OTHER INFORMATION
Item 4. Submission of Matters to a Vote of Security Holders...... 14
Item 6. Exhibits and Reports on Form 8-K......................... 14
SIGNATURE......................................................... 15
2
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
INCARA PHARMACEUTICALS CORPORATION
CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except share data)
June 30, September 30,
2000 1999
------------ ---------------
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 8,644 $ 2,407
Marketable securities - 2,553
Accounts receivable 245 282
Prepaids and other current assets 231 237
-------- --------
Total current assets 9,120 5,479
Property and equipment, net 189 2,483
Other assets - 82
-------- --------
$ 9,309 $ 8,044
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 589 $ 654
Accrued expenses 1,782 1,933
Current portion of capital lease obligations 21 488
Current portion of notes payable 27 197
-------- --------
Total current liabilities 2,419 3,272
Long-term portion of capital lease obligations 48 399
Long-term portion of notes payable - 582
Stockholders' equity:
Common stock, $.001 par value per share, 40,000,000 shares
authorized, 7,284,261 and 5,226,969 shares issued and
outstanding at June 30, 2000 and September 30, 1999,
respectively 7 5
Additional paid-in capital 88,837 81,772
Restricted stock (279) (744)
Accumulated deficit (81,723) (77,242)
-------- --------
Total stockholders' equity 6,842 3,791
-------- --------
$ 9,309 $ 8,044
======== ========
The accompanying notes are an integral part of these consolidated
financial statements.
3
INCARA PHARMACEUTICALS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)
Three Months Ended Nine Months Ended
June 30, June 30,
-------------------------- --------------------------
2000 1999 2000 1999
---------- ---------- ---------- ----------
Revenue:
Contract and license fee revenue $ - $ 188 $ 100 $ 588
------- ------- -------- --------
Costs and expenses:
Research and development 2,360 3,654 5,985 15,074
Purchased in-process research
and development - - 6,664 -
General and administrative 718 777 1,970 2,266
------- ------- -------- --------
Total costs and expenses 3,078 4,431 14,619 17,340
------- ------- -------- --------
Loss from operations (3,078) (4,243) (14,519) (16,752)
Gain on sale of division - - 9,751 -
Investment income, net 134 124 287 336
------- ------- -------- --------
Net loss $(2,944) $(4,119) $ (4,481) $(16,416)
======= ======= ======== ========
Net loss per common share:
Basic $ (0.41) $ (0.56) $ (0.75) $ (2.24)
======= ======= ======== ========
Diluted $ (0.41) $ (0.56) $ (0.75) $ (2.24)
======= ======= ======== ========
Weighted average common shares
outstanding 7,258 7,341 6,005 7,315
======= ======= ======== ========
The accompanying notes are an integral part of these consolidated
financial statements.
4
INCARA PHARMACEUTICALS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
Nine Months Ended
June 30,
-----------------------------
2000 1999
--------- ---------
Cash flows from operating activities:
Net loss $(4,481) $(16,416)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization 236 582
Purchased in-process research and development 6,664 -
Gain on sale of division (9,751) -
Loss on disposal of property and equipment 35 -
Noncash compensation 1,098 1,018
Change in assets and liabilities:
Accounts receivable 37 1,069
Prepaids and other assets 2 3
Accounts payable and accrued expenses (726) (1,368)
----------- -----------
Net cash used in operating activities (6,886) (15,112)
----------- -----------
Cash flows from investing activities:
Proceeds from sale of division 11,000 -
Proceeds from sales and maturities of marketable securities 2,553 11,414
Purchases of marketable securities - (1,044)
Purchases of property and equipment (85) (278)
----------- -----------
Net cash provided by investing activities 13,468 10,092
----------- -----------
Cash flows from financing activities:
Net proceeds from issuance of stock 102 167
Proceeds from capital leases 38 -
Repurchase of Incara stock (332) -
Advances from former parent, net - 251
Principal payments on notes payable (56) (129)
Principal payments on capital lease obligations (97) (368)
----------- -----------
Net cash used in financing activities (345) (79)
----------- -----------
Net increase (decrease) in cash and cash equivalents 6,237 (5,099)
Cash and cash equivalents at beginning of period 2,407 10,647
----------- -----------
Cash and cash equivalents at end of period $ 8,644 $ 5,548
=========== ===========
The accompanying notes are integral part of these unaudited consolidated
financial statements.
5
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
A. Basis of Presentation
---------------------
The "Company" or "Incara" refers collectively to Incara Pharmaceuticals
Corporation and its wholly owned subsidiaries, Aeolus Pharmaceuticals, Inc., a
Delaware corporation, and Renaissance Cell Technologies, Inc., a Delaware
corporation.
Incara conducts discovery and development programs in three areas: (1)
inflammatory bowel disease, using an ultra-low molecular weight heparin; (2)
liver disorders, using hepatic precursor cell therapy; and (3) small molecule
antioxidants for disorders such as stroke, asthma and chronic bronchitis.
All significant intercompany activity has been eliminated in the
preparation of the consolidated financial statements. The unaudited
consolidated financial statements have been prepared in accordance with the
requirements of Form 10-Q and Rule 10-01 of Regulation S-X. Some information
and footnote disclosures normally included in financial statements prepared in
accordance with generally accepted accounting principles have been condensed or
omitted pursuant to those rules and regulations. In the opinion of management,
the accompanying unaudited consolidated financial statements include all
adjustments (consisting only of normal recurring adjustments) necessary to
present fairly the consolidated financial position, results of operations and
cash flows of the Company. The consolidated balance sheet at September 30, 1999
was derived from the Company's audited financial statements included in the
Company's Annual Report on Form 10-K. The unaudited consolidated financial
statements included herein should be read in conjunction with the audited
consolidated financial statements and the notes thereto included in the
Company's Annual Report on Form 10-K for the fiscal year ended September 30,
1999 and in the Company's other SEC filings. Results for the interim period are
not necessarily indicative of the results for any other interim period or for
the full fiscal year.
B. Recent Accounting Pronouncements
--------------------------------
In June 1998, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards No. 133, "Accounting for Derivative
Instruments and Hedging Activities". SFAS 133 establishes accounting and
reporting standards for derivative instruments, including some derivative
instruments embedded in other contracts (collectively referred to as
derivatives), and for hedging activities. SFAS 133 will be effective for all
fiscal quarters of all fiscal years beginning after June 15, 2000, with earlier
application encouraged. The Company does not currently use derivatives, nor
does it intend in the future to use derivatives. Therefore, the Company does
not expect that the adoption of SFAS 133 will have any impact on its financial
position or results of operations.
In December 1999, the SEC issued Staff Accounting Bulletin No. 101,
"Revenue Recognition in Financial Statements," which provides guidance on the
recognition, presentation
6
and disclosure of revenue in financial statements filed with the SEC. SAB 101,
as amended by SAB 101A and SAB101B, outlines the basic criteria that must be met
to recognize revenue and provides guidance for disclosures related to revenue
recognition policies. The Company does not expect SAB 101 to have a significant
impact on the Company's revenue recognition policies.
C. Purchased In-Process Research and Development
---------------------------------------------
The acquisition cost of in-process technology that at the date of purchase
had not achieved technological feasibility and had no alternative future use was
charged to operations in the period such technology was acquired. Purchased in-
process research and development costs for the nine months ended June 30, 2000
relate to the acquisition of the minority interests of Renaissance and Aeolus
(see Note F).
D. Net Loss Per Common Share
-------------------------
The Company computes basic net loss per common share using the weighted
average number of shares of common stock outstanding during the period. The
Company computes diluted net loss per common share using the weighted average
number of shares of common and dilutive potential common shares outstanding
during the period. Potential common shares consist of stock options using the
treasury stock method and are excluded if their effect is antidilutive. For the
three-month and nine-month periods ended June 30, 2000 and 1999, the weighted
average shares outstanding used in the calculation of net loss per common share
did not include potential shares outstanding because they had the effect of
reducing net loss per common share.
E. Sale of IRL
-----------
On December 29, 1999, the Company sold its anti-infective division, known
as Incara Research Laboratories ("IRL"), to a private pharmaceutical company for
$11,000,000 in cash and the right to receive up to an additional $4,000,000 if a
compound originating from a collaboration between the Company and Merck & Co.,
Inc. reaches preclinical and clinical trial milestones. The transaction
involved the sale of assets associated with IRL, including rights under the
collaboration with Merck and the assumption of related liabilities by the
purchaser. In December 1999, the Company recognized a gain of $9,751,000 on the
sale of IRL. The Company remains contingently liable through May 2007 on debt
and lease obligations of approximately $9,000,000 assumed by the purchaser,
including the IRL facility lease in Cranbury, New Jersey.
F. Acquisitions
------------
On March 31, 2000, Incara purchased all of the minority interests of
Renaissance and Aeolus. Prior to the acquisitions, Incara owned 78.0% of
Renaissance and 65.8% of Aeolus. Incara issued 1,220,041 shares of its common
stock in exchange for the subsidiaries' minority ownership. The acquisitions
have been accounted for using the purchase method of accounting.
7
The total purchase price of $6,664,000 consisted of 1,220,041 shares of
Incara's common stock with a fair value of $5.46 per share, based on the price
of the Company's common stock at the date of acquisition. The total purchase
price was allocated to purchased in-process research and development and
immediately charged to operations because at the date of the acquisition the in-
process research purchased was in preclinical stages, feasibility had not been
established and it was deemed to have no alternative future use. Additionally,
Renaissance and Aeolus had no workforce or other tangible fixed assets.
Renaissance and Aeolus had incurred approximately $10,000,000 in research
and development costs prior to the acquisition of the minority interests by
Incara. Incara expects that it will take until at least 2006 to complete
development of all aspects of the research and that Renaissance and Aeolus will
need to spend in excess of an additional $50,000,000 to do so.
G. Stock Transactions
------------------
In May 1998, Incara acquired Transcell Technologies, Inc., which became
IRL. Incara issued the third and final installment of the purchase price of
856,861 shares of Incara common stock to the former stockholders of Transcell on
February 8, 2000. The number of shares issued was calculated using a formula
based on the average market price of Incara common stock prior to the stock
issuance date. The issuance of these additional shares did not impact the
Company's fiscal 2000 operating results, because the value of these shares was
included in the determination of the purchase price of Transcell in fiscal 1998.
In January 2000, the Company's Board of Directors authorized the repurchase
of up to $2,000,000 of Incara's common stock through the end of March 2000
through purchases on the stock market. During that period, the Company
repurchased 104,100 shares of its common stock at a cost of $332,000.
8
Item 2. Management's Discussion and Analysis of Financial Condition and
---------------------------------------------------------------
Results of Operations.
- ---------------------
Introduction
- ------------
Unless otherwise noted, the phrase "we" or "our" refers collectively to
Incara Pharmaceuticals Corporation and our wholly owned subsidiaries, Aeolus
Pharmaceuticals, Inc. and Renaissance Cell Technologies, Inc.
This Report contains, in addition to historical information, statements by
us with respect to expectations about our business and future results, which are
"forward-looking" statements under the Private Securities Litigation Reform Act
of 1995. These statements and other statements made elsewhere by us or our
representatives, which are identified or qualified by words such as "likely,"
"will," "suggests," "expects," "might," "believe," "could," "should," "would,"
"anticipates," "targets, " "plans" or similar expressions, are based on a number
of assumptions that are subject to risks and uncertainties. Actual results
could differ materially from those currently anticipated or suggested due to a
number of factors, including those set forth herein, those set forth in our
Annual Report on Form 10-K and in our other SEC filings, and including risks
relating to the early stage of products under development, uncertainties
relating to clinical trials, regulatory reviews and patent and other
intellectual property protections, the need for additional funds, competition
and dependence on collaborative partners. All forward-looking statements are
based on information available as of the date hereof, and we do not assume any
obligation to update forward-looking statements.
We conduct discovery and development programs in three areas: (1)
inflammatory bowel disease, using an ultra-low molecular weight heparin known as
OP2000; (2) liver disorders, using hepatic precursor cell therapy; and (3) small
molecule antioxidants for disorders such as stroke and chronic bronchitis.
On December 29, 1999, we sold our anti-infective division, known as Incara
Research Laboratories, or IRL, to a private pharmaceutical company for
$11,000,000 in cash and the right to receive future payments totaling up to an
additional $4,000,000 in the event a compound originating from a collaboration
with Merck & Co., Inc. reaches preclinical and clinical trial milestones. The
transaction involved the sale of assets associated with IRL, including rights
under the collaboration with Merck and the assumption of related liabilities by
the purchaser. We remain contingently liable through May 2007 on debt and lease
obligations of approximately $9,000,000 assumed by the purchaser, including the
IRL facility lease in Cranbury, New Jersey. We recognized a gain of $9,751,000
on the sale of IRL, which we recorded as other income.
On March 31, 2000, Incara acquired all of the minority interests of
Renaissance and Aeolus. Prior to the acquisition, Incara owned 78.0% of
Renaissance and 65.8% of Aeolus. Incara issued 1,220,041 shares of its common
stock for the subsidiaries' minority ownership. The acquisition has been
accounted for using the purchase method of accounting with a total purchase
price of $6,664,000. We allocated the total purchase price to purchased in-
process research and development and immediately charged it to operations
because at the date of the acquisition the in-process research purchased was in
preclinical stages, feasibility had not been
9
established and it was deemed to have no alternative future use. We estimated at
the acquisition date that Renaissance and Aeolus will need to spend in excess of
an additional $50,000,000 to complete the research and development and that it
would be at least 2006 before the research and development is completed. The
cost to complete research and development for these programs might be shared
with collaborative partners in the future.
Results of Operations
- ---------------------
We incurred net losses of $2,944,000 and $4,481,000 for the three and nine
months ended June 30, 2000, respectively. The net loss for the nine months
ended June 30, 2000 resulted from the net effect of recognizing a $9,751,000
gain on the sale of IRL in December 1999, offset by operating expenses for the
nine months of $7,955,000 and the expensing of $6,664,000 for purchased in-
process research and development in March 2000. We had net losses of $4,119,000
and $16,416,000 for the three and nine months ended June 30, 1999, respectively.
We did not have any revenue during the three months ended June 30, 2000.
Contract and license fee revenue was $100,000 and $588,000 for the nine months
ended June 30, 2000 and 1999, respectively. Substantially all of this revenue
resulted from an IRL collaboration with Merck & Co., Inc. We will not receive
any additional revenue from this collaboration, because it was sold with the
other IRL assets.
Our research and development ("R&D") expenses decreased $1,294,000 (35%) to
$2,360,000 for the for the three months ended June 30, 2000 from $3,654,000 for
the three months ended June 30, 1999. R&D expenses decreased $9,089,000 (60%)
to $5,985,000 for the nine months ended June 30, 2000 from $15,074,000 for the
nine months ended June 30, 1999. The lower expenses were primarily due to the
result of discontinuing our bucindolol development program in the fourth quarter
of fiscal 1999 and to the sale of our IRL operation in December 1999.
During the last quarter of fiscal 1999, we discontinued our bucindolol
development program and, therefore, we did not incur any bucindolol related
expenses this fiscal year. During the nine months ended June 30, 1999, we
incurred $4,820,000 of bucindolol related R&D expenses. We do not anticipate
any additional expenses for bucindolol.
Because we sold IRL at the end of December 1999, we did not incur any
significant R&D expenses for IRL between January 1, 2000 and June 30, 2000. R&D
expenses for IRL were approximately $1,376,000 for the three months ended
December 31, 1999 and for the nine months ended June 30, 2000. IRL expenses
were $1,663,000 and $6,275,000 for the three and nine months ended June 30,
1999, respectively. We do not expect any additional expense for IRL in the
future.
We incurred $433,000 and $1,166,000 of R&D expenses for OP2000 during the
three months and nine months ended June 30, 2000, respectively. OP2000 expenses
were $55,000 and $125,000 for the three months and nine months ended June 30,
1999, respectively. The higher expenses in fiscal 2000 were primarily due to
costs incurred in connection with our Phase 1
10
clinical trials that began in October 1999 and were completed in April 2000, as
well as preparation costs for the Phase 2/3 clinical trial which we plan to
begin in fall of 2000.
R&D expenses for our liver cell program decreased $9,000 (4%) to $237,000
for the three months ended June 30, 2000 from $248,000 for the three months
ended June 30, 1999. These R&D expenses increased $154,000 (27%) to $730,000
for the nine months ended June 30, 2000 from $576,000 for the nine months ended
June 30, 1999. The higher expenses in the current fiscal year resulted
primarily from more R&D staff time being devoted to the program.
R&D expenses for our antioxidant program increased $268,000 (69%) to
$657,000 for the three months ended June 30, 2000 from $389,000 for the three
months ended June 30, 1999. This increase for the quarter was primarily due to
expenses associated with the selection of a lead antioxidant compound. R&D
expenses for our antioxidant program decreased $403,000 (25%) to $1,231,000 for
the nine months ended June 30, 2000 from $1,634,000 for the nine months ended
June 30, 1999. The decrease in expenses from fiscal 1999 to fiscal 2000 was
primarily due to the reduction of outside contract services and sponsored
research costs.
General and administrative ("G&A") expenses decreased $59,000 (8%) to
$718,000 for the three months ended June 30, 2000 from $777,000 for the three
months ended June 30, 1999. G&A expenses decreased $296,000 (13%) to $1,970,000
for the nine months ended June 30, 2000 from $2,266,000 for the nine months
ended June 30, 1999. The higher G&A expenses in fiscal 1999 were primarily for
expenses related to the bucindolol program, which was terminated in the last
quarter of fiscal 1999.
In May 1998, we acquired Transcell Technologies, Inc., which became IRL.
We issued the third and final installment of the purchase price of 856,861
shares of Incara common stock to the former stockholders of Transcell on
February 8, 2000. The number of shares issued was calculated using a formula
based on the market price of Incara common stock prior to the stock issuance
date. The issuance of these additional shares did not impact our fiscal 2000
operating results, because the value of these shares was included in the
determination of the purchase price of Transcell in fiscal 1998.
In March 2000, we recognized an in-process research and development charge
of $6,664,000 as a result of the acquisition of the minority interests of
Renaissance and Aeolus. We allocated the total purchase price to in-process
research and development because at the date of acquisition it had not reached
feasibility and it had no alternative future use. Renaissance and Aeolus spent
approximately $10,000,000 through March 2000 and estimate that in excess of
$50,000,000 over at least the next five years will need to be spent to complete
the research and development. The cost to complete a portion of this research
and development might be shared with a collaborative partner in the future.
Liquidity and Capital Resources
- --------------------------------
At June 30, 2000, we had cash and cash equivalents and marketable
securities of $8,644,000, an increase of $3,684,000 from September 30, 1999.
Cash increased due to the receipt of $11,000,000 from the sale of IRL, offset by
operating costs for the nine months. We
11
believe we have adequate financial resources to fund our current operations at
least into calendar 2001.
We expect to incur substantial additional costs and losses over the next
few years. Our cash requirements for subsequent periods will depend on numerous
factors, particularly the progress of our research and development programs.
Significant additional funds will be required for us to continue our clinical
program evaluating the use of OP2000 and to complete preclinical activities, and
to begin clinical trials for our liver precursor cell and antioxidant programs.
We have completed two Phase 1 clinical trials for OP2000, the most recent
having been completed in April 2000. These trials looked at single and multiple
dose administrations of the drug, and preliminary results indicate that we will
be able to give OP2000 on a once-a-day basis. Assuming we have adequate
financial resources, we plan to begin a Phase 2/3 safety and efficacy trial in
ulcerative colitis patients in fall of 2000. We have an exclusive license from
Opocrin, in all countries other than Japan and Korea, for an issued patent
claiming certain oligosaccharides derived from heparin and their use in
antiatherosclerotic activity to develop and commercialize OP2000. We are aware
of a recently issued patent claiming the use of certain fractions of heparin for
the treatment of inflammatory bowel disease. We do not believe OP2000 falls
within the scope of this patent. If OP2000 were to be determined to fall within
the scope of this patent and if the patent's claims were found to be valid, we
would have to license this patent in order to commercialize OP2000. If this
were the case, we might not be able to license this patent at a reasonable cost,
which would result in our not being able to market OP2000.
Incara is exploring two patient populations for the initial clinical trials
of liver precursor cell transplantation. The first group consists of infants
with life-threatening inborn errors of metabolism who are too young for liver
transplants. This patient population represents a group with limited treatment
alternatives where improvement in patient condition and production of the
missing gene products would demonstrate the function of the transplanted cells.
The second series of clinical trials being planned involves adults with such
severe cirrhosis and other forms of chronic liver failure that they could become
candidates for a transplant. Assuming we have adequate financial resources,
Incara plans to begin these initial clinical trials in 2001.
In a model of ischemic stroke, where the middle cerebral artery of a rat is
blocked for 90 minutes and then unblocked, our lead antioxidant compound reduced
infarct size significantly when introduced as late as 7 1/2 hours after the
start of the stroke. Stroke is a form of ischemia/reperfusion injury, and this
compound is also highly active in a model of liver ischemia/reperfusion injury.
We are currently evaluating another antioxidant compound and we anticipate
selecting the most promising drug candidate for stroke in fall of 2000, once
more data is available. Assuming satisfactory completion of the preclinical
studies and assuming we have adequate financial resources, we intend to initiate
Phase 1 clinical trials for an antioxidant compound in 2001.
We might acquire other products, technologies or businesses that complement
our existing or planned products or programs, although we currently have no
understanding, commitment or agreement with respect to any such acquisitions.
12
We intend to seek additional capital necessary to execute our business plan
through one or more potential sources, including the sale of common or preferred
stock in private or public equity offerings and from new collaborations related
to one or more of our product development programs. Adequate funds might not be
available at all or on terms acceptable or favorable to us. It is currently
difficult for biotechnology companies to raise funds in the equity markets. Any
additional equity financing, if available, would likely result in substantial
dilution to Incara's stockholders. If we are successful in obtaining
collaborations for any of our programs, we expect to relinquish rights to
technologies, product candidates or markets which we might otherwise develop
ourselves. If we are unable to enter into new collaborations or raise
additional capital to support our current level of operations, we might be
required to scale back, delay or discontinue one or more of our research and
development programs, such as our proposed clinical trials, or obtain funds on
terms that are not favorable to us, which could have a material adverse affect
on our business. Reduction or discontinuation of research and development
programs could result in additional charges, which would be reflected in the
period of the reduction or discontinuation.
In January 2000, our Board of Directors authorized the repurchase of up to
$2,000,000 of our common stock during the following two months through purchases
on the stock market. During that period, we repurchased 104,100 shares of our
common stock at a cost of $332,000.
13
PART II. OTHER INFORMATION
Item 4. Submission of Matters to a Vote of Security Holders
---------------------------------------------------
The Annual Meeting of Stockholders of the Company was held on April 6,
2000. The following is a brief description of each matter voted upon at the
meeting and the number of affirmative votes and the number of negative votes
cast with respect to each matter.
(a) The stockholders elected the following persons as directors of the Company:
Clayton I. Duncan; Joseph J. Ruvane, Jr.*; David B. Sharrock; Edgar H.
Schollmaier; and Stephen M. Prescott. The votes for and against (withheld)
each nominee were as follows:
Votes Votes Votes
Nominee For Withheld Abstained
------- --- -------- ---------
Clayton I. Duncan 4,052,184 1,900 0
Joseph J. Ruvane, Jr.* 4,052,184 1,900 0
David B. Sharrock 4,052,184 1,900 0
Edgar H. Schollmaier 4,052,184 1,900 0
Stephen M. Prescott 4,052,184 1,900 0
_____________________
* Mr. Ruvane passed away in June 2000.
(b) The stockholders approved an amendment to the Incara Pharmaceuticals
Corporation 1995 Employee Stock Purchase Plan to increase the number of
shares of Common Stock reserved for issuance thereunder from 200,000 shares
to 400,000 shares with 4,025,396 shares voting for, 18,963 shares voting
against and 9,725 shares abstained.
(c) The stockholders ratified the appointment of PricewaterhouseCoopers LLP as
the independent auditors of the Company for the fiscal year ending
September 30, 2000 with 4,051,065 shares voting for, 2,120 shares voting
against and 899 shares abstained.
Item 6. Exhibits and Reports on Form 8-K.
--------------------------------
(a) Exhibits
27 Financial Data Schedule, which is submitted electronically to the
Securities and Exchange Commission for information only and not
filed.
(b) No reports on Form 8-K were filed by the Company during the three months
ended June 30, 2000.
14
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
INCARA PHARMACEUTICALS CORPORATION
Date: July 28, 2000 By: /s/ Richard W. Reichow
---------------------------------------------
Richard W. Reichow, Executive Vice President,
Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
15